Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2019 Jan 29;12:921–932. doi: 10.2147/OTT.S180507

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2019 Ma et al. This work is published and licensed by Dove Medical Press Limited

The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.

PMC Copyright notice

Kaplan–Meier analyses of overall survival (OS) and progression-free survival (PFS) in all eligible cases.

Notes: In the training set, (A) the 3-year OS rate was 32.7% for CCNY-positive (CCNY[+]) patients and 72.9% for CCNY-negative (CCNY[−]) patients (P<0.01). (B) The 3-year PFS rate was 30% for CCNY[+] patients and 62% for CCNY[−] patients (P<0.01). In the validation set, (C) the 3-year OS rate was 27.7% for CCNY[+] patients and 44.1% for CCNY[−] patients (P<0.01). (D) The 3-year PFS rate was 20% for CCNY[+] patients and 36.2% for CCNY[−] patients (P<0.01). The blue line is CCNY-positive patients and the green line is CCNY-negative patients.